Biofrontera, Inc. (DE:AI10)
NASDAQ:AI10
AI10 Stock Chart & Stats
€0.80
€0.00(0.00%)
At close: 4:00 PM EST
€0.80
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€0.79 - €0.80
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€10.67M
Enterprise Value€13.97M
Total Cash (Recent Filing)€6.32M
Total Debt (Recent Filing)€7.72M
Price to Earnings (P/E)―
Beta-0.93
Next Earnings
Aug 07, 2026EPS Estimate
-0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.12
Shares Outstanding12,803,344
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.55
Price to Sales (P/S)0.14
P/FCF Ratio-0.43
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€5.25Price Target Upside556.29% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.15
Revenue Forecast (FY)€39.63M
Bulls Say, Bears Say
Bulls Say
Clinical Trial ReadoutsData from the Phase 3 extremities trial and the Phase 2b acne trial expected early in 2026 could validate new indications and materially expand commercial opportunity.
Operational Cost SavingsRestructuring of agreements with former parent Biofrontera AG is expected to deliver cost savings and operational efficiencies that improve margins and cash flow flexibility.
Regulatory FilingA supplemental NDA submission for the extremities indication projected in mid-2026 could enable label expansion and broader prescribing, supporting future revenue growth.
Bears Say
Demand Timing VolatilityCustomer stockpiling ahead of an anticipated price increase could create a pull-forward effect, producing revenue volatility once the stocking period ends.
Profitability PressureA larger-than-planned net loss underscores ongoing profitability challenges that could weigh on the stock until margins show sustained improvement.
Top-line Momentum RiskIn-line quarterly revenue suggests limited top-line momentum, increasing the risk that growth expectations may not be met.
Biofrontera News
AI10 FAQ
What was Biofrontera, Inc.’s price range in the past 12 months?
Biofrontera, Inc. lowest stock price was €0.79 and its highest was €0.80 in the past 12 months.
What is Biofrontera, Inc.’s market cap?
Biofrontera, Inc.’s market cap is €10.67M.
When is Biofrontera, Inc.’s upcoming earnings report date?
Biofrontera, Inc.’s upcoming earnings report date is Aug 07, 2026 which is in 42 days.
How were Biofrontera, Inc.’s earnings last quarter?
Biofrontera, Inc. released its earnings results on May 14, 2026. The company reported -€0.352 earnings per share for the quarter, missing the consensus estimate of -€0.099 by -€0.254.
Is Biofrontera, Inc. overvalued?
According to Wall Street analysts Biofrontera, Inc.’s price is currently Undervalued.
Does Biofrontera, Inc. pay dividends?
Biofrontera, Inc. does not currently pay dividends.
What is Biofrontera, Inc.’s EPS estimate?
Biofrontera, Inc.’s EPS estimate is -0.09.
How many shares outstanding does Biofrontera, Inc. have?
Biofrontera, Inc. has 12,803,344 shares outstanding.
What happened to Biofrontera, Inc.’s price movement after its last earnings report?
Biofrontera, Inc. reported an EPS of -€0.352 in its last earnings report, missing expectations of -€0.099. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Biofrontera, Inc.?
Currently, no hedge funds are holding shares in DE:AI10
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Biofrontera, Inc.
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. It offers Ameluz, BF-RhodoLED, RhodoLED XL lamp series, and RhodoLED Lamps, which are used for the treatment of actinic keratosis, which are pre-cancerous skin lesions. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.
AI10 Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlighted a clear, material improvement in core commercial and financial metrics (17% revenue growth, ~16% unit growth, gross margin expansion to ~80%, near-zero operating cash use) alongside meaningful clinical and regulatory progress (sNDA acceptance for sBCC with a PDUFA in September, positive AK Phase III results, encouraging acne data). These positives are tempered by elevated SG&A and operating expenses, ongoing patent/legal costs and a continued going concern qualification with limited liquidity. On balance the transform-driven revenue and margin gains, near-term regulatory catalysts, and improved cash performance materially outweigh the challenges, supporting a constructive view of the company's trajectory while recognizing remaining execution and financing risks.View all DE:AI10 earnings summariesAI10 Stock 12 Month Forecast
Average Price Target
€5.25
▲(556.29% Upside)
Technical Analysis
Prophase Labs
―
TherapeuticsMD
―
RedHill Biopharma
―
Cosmos Holdings
―
Gelteq Limited
―
Options Prices
Currently, No data available
---